Quantcast
Friday, November 1, 2024

CDC Admits Unboosted Vaccines Worse than Nothing at All

'Pfizer CEO Albert Bourla has admitted that his company's product does not protect against Omicron... '

(Joshua Paladino, Headline USA) Those who receive both COVID-19 shots may face a higher risk of infection from the Omicron variant than people who never got the injections, according to a study by CDC researchers in Atlanta.

The data indicates that after the shot’s efficacy subsides—in about three to six months according to current estimates—a vaccinated person becomes more likely to contract Omicron than an unvaccinated person.

This rebound effect occurs right when the vaccinated person becomes eligible for a booster, at which time the first two doses become, without the additional shot, a liability.

Pfizer BioNTech’s shot became worse than useless after three months whereas Moderna‘s became worse than useless after six months due to the shot’s higher dosage of the mRNA spike protein.

The same study, published in the Journal of the American Medical Association, found that vaccinated people fared better against the Delta variant than unvaccinated people for all studied time frames.

Even though the COVID-19 shots and booster show near-zero efficacy against the Omicron variant, the federal government’s health agencies still recommend them.

By contrast, the Food and Drug Administration revoked two emergency-use authorizations for Regeneron and Eli Lilly’s monoclonal antibody therapies with the justification that they are “highly unlikely to be active” against Omicron.

The monoclonal antibody treatments, however, have not caused extensive, life-threatening side effects.

Pfizer CEO Albert Bourla has admitted that his company’s product does not protect against Omicron, yet the federal government has not pulled its authorization.

Todd Zywicki, a law professor at George Mason University and natural-immunity advocate, noted that several other studies have come to the same conclusion.

Copyright 2024. No part of this site may be reproduced in whole or in part in any manner other than RSS without the permission of the copyright owner. Distribution via RSS is subject to our RSS Terms of Service and is strictly enforced. To inquire about licensing our content, use the contact form at https://headlineusa.com/advertising.
- Advertisement -

TRENDING NOW

TRENDING NOW